SiteOne Therapeutics, Inc

SiteOne Therapeutics, Inc., based in Bozeman, MT, is a clinical-stage biotechnology company focused on developing innovative treatments for pain and sensory hyperexcitability disorders by targeting the peripheral nervous system. Their pipeline includes selective sodium channel inhibitors, such as Nav17 and Nav18, which aim to provide effective analgesia with reduced side effects and lower risk of abuse compared to traditional central nervous system treatments.

Beyond pain management, SiteOne's research addresses a range of conditions associated with peripheral sensory hyperexcitability, including chronic cough, itch, and gastrointestinal issues. By expanding their therapeutic approach to encompass all phases of the action potential in peripheral sensory neurons, SiteOne is positioned to create groundbreaking non-opioid treatments for various neuropathic and visceral pain conditions.

Generated from the website